idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
OPERA research project launched to further develop antiviral active substances
An interdisciplinary consortium consisting of TWINCORE, Centre for Experimental and Clinical Infection Research, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, the University of Lübeck and Hannover Medical School, is receiving funding of around €999,000 from the Volkswagen Foundation. Under the leadership of Prof. Thomas Pietschmann, the team plans to optimise active substances against the respiratory syncytial virus (RSV) over the next two years.
RSV causes respiratory infections that can be particularly severe in young children and older people. According to the World Health Organisation (WHO), around 3.6 million children under the age of five are treated in hospital for RSV infections every year, and 100,000 of them die as a result of the infection. Currently, the only treatment available is supportive care, such as oxygen therapy. The consortium therefore aims to develop new treatment options as part of the ‘OPERA’ (optimising pan-entry RSV antivirals) project.
‘In order to enter human cells, the virus must fuse with the membrane,’ says Prof. Pietschmann. He is director of the Institute for Experimental Virology at TWINCORE in Hanover and heads the research project. The fusion protein, or F protein for short, plays an essential role in this process. In previous work, the research team has identified inhibitors that can very effectively inhibit this step of infection at the cell surface. However, they are not very effective against alternative fusion inside the cell, which likely occurs in an environment with lower pH. ‘That's why we want to optimise the fusion inhibitors so that they are active in a wider pH range,’ says Prof. Anna Hirsch, head of the Drug Design and Optimisation Department at HIPS. ‘This would significantly improve the effectiveness of the inhibitors.’
In addition, a formulation suitable for inhalation is to be developed. ‘This will allow the active ingredient to reach the lungs quickly and in a targeted manner,’ says Prof. Martin Empting, who heads the ‘Antiviral & Antivirulence Agents’ working group at HIPS. The active ingredient will first be comprehensively tested in human primary cells. Additionally analyzing absorption, distribution, metabolism, excretion and toxicity (ADMET) allows to understand and optimize pharmacokinetics and pharmacodynamics (PK/PD) of the substance. Its efficacy will then be demonstrated in animal models. ‘This is the milestone for the transition to industrial development,’ says Dr Katharina Rox, head of the Pharmacokinetics/Pharmacodynamics research group at the HZI. Once the defined milestones have been reached, the industrial partner ENYO Pharma SA will take over the preclinical development up to the first human studies.
In addition to Prof. Thomas Pietschmann's team, which is conducting the virological profiling, various other working groups are involved in this project. The teams led by Prof. Anna Hirsch and Prof. Martin Empting at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) are contributing their expertise in the fields of medicinal chemistry and computer-aided drug optimisation. Prof. Thomas Krey's laboratory at the University of Lübeck is working on the structural biology aspects of the F protein. Dr Katharina Rox is conducting the pharmacological studies at the HZI in Braunschweig. Prof. Gesine Hansen, Medical Director of the Clinic for Paediatric Pneumology, Allergology and Neonatology at Hannover Medical School, is responsible in particular for demonstrating the in vivo proof of concept in a lung infection model. The biotechnology company ENYO Pharma SA from Lyon, France, is responsible for the subsequent industrial development. The Translational Project Management Office (TPMO) of the German Center for Infection Research (DZIF) supports the consortium and accompanies the project with professional, translational project management by Dr Marina Steindorff.
Prof. Thomas Pietschmann
+49 (0)511-220027-130
thomas.pietschmann@twincore.de
https://twincore.de/news/optimised-active-substances-against-rsv | This press release on twincore.de
RSV induces cell fusion (syncytia) via its F protein; fusion inhibitors are promising antivirals. Im ...
Quelle: ©TWINCORE/S.Haid & A.Carpentier
Merkmale dieser Pressemitteilung:
Journalisten, Wirtschaftsvertreter, Wissenschaftler, jedermann
Biologie, Chemie, Medizin
überregional
Forschungsprojekte, Kooperationen
Englisch
RSV induces cell fusion (syncytia) via its F protein; fusion inhibitors are promising antivirals. Im ...
Quelle: ©TWINCORE/S.Haid & A.Carpentier
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
